Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: Randomized phase II trial 40953 of the European organisation for research and treatment of cancer gastrointestinal group and the arbeitsgemeinschaft internistische onkologie

Journal of Clinical Oncology

Volumn 25, Issue 18, 2007, Pages 2580-2585

  Lutz, Manfred P ^a   Wilke, Hansjochen ^a   Wagener, D J Theo ^a   Vanhoefer, Udo ^a   Jeziorski, Krzysztof ^a   Hegewisch Becker, Susanna ^a   Balleisen, Leopold ^a   Joossens, Eric ^a   Jansen, Rob L ^a   Debois, Muriel ^a   Bethe, Ullrich ^a   Praet, Michel ^a   Wils, Jacques ^a   Van Cutsem, Eric ^a  

^a KLINIKEN ESSEN MITTE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID;

ADULT; AGED; ALOPECIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RESEARCH; CANCER STAGING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG SAFETY; FEMALE; FEVER; FOLLOW UP; GRANULOCYTE; HUMAN; INFECTION; LETHARGY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMACH CANCER; STOMATITIS; THROMBOCYTE; TREATMENT RESPONSE; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; EUROPE; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 34447255242     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.11.1666     Document Type: Article

References (23)

1. Macdonald JS: Gastric cancer: New therapeutic options. N Engl J Med 355:76-77, 2006
2. Cunningham D, Allum WH, Stenning SP, et al: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11-20, 2006
3. Glimelius B, Ekstrom K, Hoffman K, et al: Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8:163-168, 1997
4. Pyrhonen S, Kuitunen T, Nyandoto P, et al: Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer 71:587-591, 1995
5. Murad AM, Santiago FF, Petroianu A, et al: Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72:37-41, 1993
6. Kohne CH, Wils J, Lorenz M, et al: Randomized phase III study of high-dose fluorouracil given as a weekly 24-hour infusion with or without leucovorin versus bolus fluorouracil plus leucovorin in advanced colorectal cancer: European Organization of Research and Treatment of Cancer Gastrointestinal Group Study 40952. J Clin Oncol 21:3721-3728, 2003
7. Thirion P, Michiels S, Pignon JP, et al: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: An updated meta-analysis. J Clin Oncol 22:3766-3775, 2004
8. Waters JS, Norman A, Cunningham D, et al: Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: Results of a randomized trial. Br J Cancer 80:269-272, 1999
9. Webb A, Cunningham D, Scarffe JH, et al: Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15:261-267, 1997
10. Ardalan B, Chua L, Tian EM, et al: A phase II study of weekly 24-hour infusion with high-dose fluorouracil with leucovorin in colorectal carcinoma. J Clin Oncol 9:625-630, 1991
11. Haas NB, Hines JB, Hudes GR, et al: Phase I trial of 5-fluorouracil by 24-hour infusion weekly. Invest New Drugs 11:181-185, 1993
12. Vanhoefer U, Wilke H, Weh HJ, et al: Weekly high-dose 5-fluorouracil and folinic acid as salvage treatment in advanced gastric cancer. Ann Oncol 5:850-851, 1994
13. Wilke H, Vanhoefer U, Fink U: Weekly high-dose FU/folinic acid (HD-FU/FA) and cisplatin (C): A safe and active combination for advanced gastric cancer (GC). Presented at Sec Intern Conf on Biol, Prev and Treatm of GI Malign, Cologne, Germany, February 5, 1995
14. Vanhoefer U, Rougier P, Wilke H, et al: Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 18:2648-2657, 2000
15. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989
16. Kelsen D, Atiq OT, Saltz L, et al: FAMTX versus etoposide, doxorubicin, and cisplatin: A random assignment trial in gastric cancer. J Clin Oncol 10:541-548, 1992
17. Ross P, Nicolson M, Cunningham D, et al: Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. J Clin Oncol 20: 1996-2004, 2002
18. Mitry E, Taieb J, Artru P, et al: Combination of folinic acid, 5-fluorouracil bolus and infusion, and cisplatin (LV5FU2-P regimen) in patients with advanced gastric or gastroesophageal junction carcinoma. Ann Oncol 15:765-769, 2004
19. Moehler M, Eimermacher A, Siebler J, et al: Randomised phase II evaluation of irinotecan plus high-dose 5-fluorouracil and leucovorin (ILF) vs 5-fluorouracil, leucovorin, and etoposide (ELF) in untreated metastatic gastric cancer. Br J Cancer 92:2122-2128, 2005
20. Al-Batran SE, Atmaca A, Hegewisch-Becker S, et al: Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 22:658-663, 2004
21. Roth AD, Maibach R, Fazio N, et al: 5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: A phase I-II trial. Ann Oncol 15:759-764, 2004
22. Roth AD, Maibach R, Martinelli G, et al: Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma: Swiss Group for Clinical Cancer Res (SAKK), and the European Institute of Oncology (EIO). Ann Oncol 11:301-306, 2000
23. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al: Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group. J Clin Oncol 24: 4991-4997, 2006